Abstract

Blood–brain barrier (BBB) is a natural protective membrane that prevents central nervous system (CNS) from toxins and pathogens in blood. However, the presence of BBB complicates the pharmacotherapy for CNS disorders as the most chemical drugs and biopharmaceuticals have been impeded to enter the brain. Insufficient drug delivery into the brain leads to low therapeutic efficacy as well as aggravated side effects due to the accumulation in other organs and tissues. Recent breakthrough in materials science and nanotechnology provides a library of advanced materials with customized structure and property serving as a powerful toolkit for targeted drug delivery. In-depth research in the field of anatomical and pathological study on brain and BBB further facilitates the development of brain-targeted strategies for enhanced BBB crossing. In this review, the physiological structure and different cells contributing to this barrier are summarized. Various emerging strategies for permeability regulation and BBB crossing including passive transcytosis, intranasal administration, ligands conjugation, membrane coating, stimuli-triggered BBB disruption, and other strategies to overcome BBB obstacle are highlighted. Versatile drug delivery systems ranging from organic, inorganic, and biologics-derived materials with their synthesis procedures and unique physio-chemical properties are summarized and analyzed. This review aims to provide an up-to-date and comprehensive guideline for researchers in diverse fields, offering perspectives on further development of brain-targeted drug delivery system.

Details

Title
The blood–brain barrier: Structure, regulation and drug delivery
Author
Wu, Di 1   VIAFID ORCID Logo  ; Chen, Qi 2   VIAFID ORCID Logo  ; Chen, Xiaojie 2 ; Han, Feng 3 ; Chen, Zhong 2   VIAFID ORCID Logo  ; Wang, Yi 1   VIAFID ORCID Logo 

 Zhejiang Chinese Medical University, Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Hangzhou, China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924); The Third Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Rehabilitation Medical Center, Hangzhou, China (GRID:grid.495377.b) 
 Zhejiang Chinese Medical University, Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Hangzhou, China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924) 
 Nanjing Medical University, Key Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984) 
Pages
217
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2819158292
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.